MNG460
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.300
- PROTEIN_SECRETION+0.285
- MYC_TARGETS_V1+0.231
- MITOTIC_SPINDLE+0.224
- MTORC1_SIGNALING+0.204
- HEDGEHOG_SIGNALING+0.162
- MYC_TARGETS_V2+0.155
- ANDROGEN_RESPONSE+0.152
- GLYCOLYSIS+0.147
- HYPOXIA+0.146
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.481
- INTERFERON_GAMMA_RESPONSE-0.460
- INFLAMMATORY_RESPONSE-0.406
- INTERFERON_ALPHA_RESPONSE-0.379
- IL6_JAK_STAT3_SIGNALING-0.332
- COMPLEMENT-0.307
- TNFA_SIGNALING_VIA_NFKB-0.271
- P53_PATHWAY-0.261
- COAGULATION-0.255
- KRAS_SIGNALING_UP-0.243
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG219 | — | — | 0.845 |
| 2 | MDT-AP-0194 | Med | Medulloblastoma | 0.810 |
| 3 | MNG1055 | — | — | 0.808 |
| 4 | SRR5088894 | — | — | 0.798 |
| 5 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.796 |
| 6 | TCGA-77-6843-01A-11R-1949-07 | — | cohortSQ2 | 0.794 |
| 7 | SRR10900577 | — | — | 0.792 |
| 8 | 28541e4e-2e2b-4772-9566-acf35b31a581 | — | — | 0.792 |
| 9 | SJEPD003_D.RNA-Seq | EPN | Supratentorial EPN | 0.787 |
| 10 | 15d39440-6bb8-4ecb-add1-9ae8b007dc70 | — | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.285 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.231 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.224 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.204 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.162 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.155 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.152 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.147 | Inavolisib | — uncovered |
| HYPOXIA | 0.146 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.142 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.141 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.124 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.122 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.118 | Remibrutinib | — uncovered |
| PEROXISOME | 0.021 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.017 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.009 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.005 | Temsirolimus | — uncovered |